Gujarat Kidney and Super Speciality Ltd
The company executed Parekhs Hospital Private Limited as Wholly Own Subsidiary of Gujarat Kidney and super speciality Limited on 22nd March 2026
M&A
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 23 Mar 2026, 03:10 PM IST · BSE ID: 9fa511dc-e981-4db9-a9ac-6a454a720c52
View Original BSE Filing (PDF)
💡
In Simple Terms
Gujarat Kidney bought a hospital business called Parekhs Hospital for Rs. 77 Crore and now fully owns it.
🤖 AI Summary
- Gujarat Kidney acquired Parekhs Hospital as 100% subsidiary on 22 March 2026 for Rs. 77,00,00,000 cash
- Parekhs Hospital incorporated 13 January 2006; medical and healthcare service provider in Ahmedabad, Gujarat
- Target company paid-up capital Rs. 25,50,000; turnover FY 2024-25: Rs. 25,66,69,000
- Acquisition aims to strengthen healthcare sector presence and diversify Gujarat Kidney's business portfolio
- Not classified as related party transaction; no government approvals required
🔢 Key Numbers — exact figures from BSE filing, not rounded
Acquisition Cost
Rs. 77,00,00,000
Shareholding Acquired
100% (255,000 equity shares)
Target Company Paid-up Capital
Rs. 25,50,000
Parekhs Hospital FY 2024-25 Turnover
Rs. 25,66,69,000
Parekhs Hospital FY 2023-24 Turnover
Rs. 26,35,59,000
-2.62
Target Company Incorporation Date
13 January 2006
🏢 How This Affects the Company
Acquisition expands Gujarat Kidney's operational footprint in healthcare services sector. Target company brings established medical services infrastructure and patient base in Ahmedabad region into consolidated entity.
Rs. 77,00,00,000 cash outflow for acquisition. Target company reported FY 2024-25 turnover of Rs. 25,66,69,000, contributing incremental revenue stream to consolidated operations post-acquisition.
Acquisition brings Parekhs Hospital's medical facilities, staff, and operational infrastructure under Gujarat Kidney's management. Consolidation of two healthcare entities enables unified operational protocols and resource optimization.
Execution of acquisition exposes Gujarat Kidney to operational integration risks including staff retention, patient migration, and clinical governance harmonization. Turnover volatility in target company (Rs. 24.06 Cr to Rs. 26.36 Cr) indicates revenue sensitivity.
👥 What This Means For Shareholders
✅
Action Required
No immediate shareholder action required. Monitor Q4 FY26 results filing for consolidated financial impact and management commentary on integration progress.
👤
Who Is Affected
All Gujarat Kidney shareholders. Equity base diluted post-acquisition through Rs. 77 Crore cash deployment. Consolidated financials from Q4 FY26 onwards will reflect Parekhs Hospital operations proportionally.
🔍
Management Signal
Deliberate portfolio diversification into acquired healthcare assets indicates management intent to expand beyond core operations and build multi-entity healthcare services platform.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q4 FY26 results filing — verify consolidated financials and management integration commentary post-acquisition
Regulation 31A(10) promoter reclassification if Parekhs promoters reclassify post-acquisition completion
H1 FY27 results — track combined revenue contribution and synergy realization metrics
MEDIUM RISK
Acquisition execution complete but integration execution pending. Target revenue volatility and substantial capital deployment require demonstrated synergy and margin accretion.
💡 Investor Takeaway
Gujarat Kidney completed Rs. 77,00,00,000 cash acquisition of Parekhs Hospital as wholly owned subsidiary on 22 March 2026. Target entity generated Rs. 25,66,69,000 revenue in FY 2024-25. Acquisition consolidates healthcare operations; integration execution and synergy realization will determine long-term value creation.
⚖️ Strengths & Concerns
✅ Positives
- Acquired entity has 20-year operating history since January 2006 with established medical service infrastructure and patient base.
- Turnover of Rs. 25,66,69,000 in FY 2024-25 demonstrates revenue-generating capability and profitability in healthcare segment.
⚠️ Concerns
- FY 2024-25 turnover Rs. 25,66,69,000 shows decline from FY 2023-24 (Rs. 26,35,59,000), indicating potential revenue pressure.
- Substantial Rs. 77 Crore cash outlay for acquisition of entity generating ~Rs. 25 Crore annual turnover requires clear synergy demonstration.